Skip to main content

TriSalus Life Sciences, Inc.

TLSIW
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001826667

In the last 90 days, TriSalus Life Sciences, Inc. insiders filed 1 open-market purchase and 3 sales; 5 institutions reported holding it in 13F filings for Q2 2026, worth $798.0K in total; no superinvestor holds it.

Other share classesTLSI

Key figures

Market capClose on Nov 17, 2026
$141.6M
Insider buysLast 90 days, $112.0K in total
1
Insider sellsLast 90 days, $4.11K in total
3
13F holdersQ2 2026, −2 vs. previous quarter
5
13F valueReported value at the end of Q2 2026
$798.0K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$45.2M
+53.4% year over year
Net income, FY2025
-$39.2M
No comparable prior period
Free cash flow, FY2025
-$18.9M
No comparable prior period
Revenue, Q3 FY2026
$12.9M
+11.3% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $39.2M (86.9% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
16.2K
Shares sold short
Change
+5.33K
+48.9% vs. previous
Days to cover
12.42
At average daily volume

Superinvestors holding TLSIW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding TLSIW at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by TriSalus Life Sciences, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)8:16 AM ETNov 124 daysWahlstrom MatsDirectorPPurchase+50.0K$2.24+$112.0K+33.9%197.6K after
Oct 7, 2026 (view filing)4:02 PM ETOct 52 daysCox Bryan F.Chief of ResearchSSale−296$4.39−$1.30K−0.2%162.8K after
Oct 7, 2026 (view filing)4:02 PM ETOct 52 daysMarshak RichardChief Commercial OfficerSSale−325$4.39−$1.43K−0.3%128.0K after
Oct 7, 2026 (view filing)4:02 PM ETOct 52 daysStevens JenniferChief Regulatory OfficerSSale−316$4.39−$1.39K−0.3%123.8K after
May 19, 2026 (view filing)May 154 daysMarshak RichardChief Commercial OfficerSSale−543$2.67−$1.45K−0.4%125.1K after
May 18, 2026 (view filing)May 153 daysWahlstrom MatsDirectorPPurchase+60.0K$2.53+$151.8K+68.5%147.6K after
May 18, 2026 (view filing)May 153 daysStansky Michael PDirectorPPurchase+410.0K$2.50+$1.02M+49.4%1.24M after
May 18, 2026 (view filing)May 153 daysStansky Michael PDirectorPPurchase+200.0K$2.50+$500.0K+100.2%399.7K after
May 18, 2026 (view filing)May 153 daysSzela Mary TCEO and PresidentPPurchase+39.7K$2.59+$102.8K+3.9%1.07M after
May 18, 2026 (view filing)May 153 daysPatience DavidChief Financial OfficerPPurchase+7.10K$2.43+$17.3K+2.6%275.8K after

Top 10 13F holders, Q2 2026

See all 5 holders

The largest institutional positions in TriSalus Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding TLSIW in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Cerity Partners LLC827,590$662.1K0.00%00.0%Unchanged
Aristeia Capital LLC74,826$56.9K0.00%+46,210+161.5%Added
Vestcor Inc70,832$54.0K0.00%00.0%Unchanged
Fort Baker Capital Management LP26,374$21.1K0.00%00.0%Unchanged
Toronto Dominion Bank5,170$3.93K0.00%00.0%Unchanged